English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

One of the key pathogenic mechanisms of the arterial hypertension (AH) development in patients with metabolic syndrome is the activation of the renin-angiotensin-aldosterone system (RAAS). According to these advantages we need to use drugs inhibiting the RAAS in the treatment of AH patients. This article demonstrates the information about the new Angiotensin II receptor blocker (azilsartan) application in AH patients with metabolic disorders. There are several studies showing the high antihypertensive efficiency of azilsartan as compared with other antihypertensive drug classes in patients with obesity and metabolic disorders. According to the pilot studies, azilsartan has additional positive metabolic effects: increases tissue sensitivity to insulin and reduces body fat mass.

sistemnye gipertenzii

The treatment options of the new angiotensin II receptor blocker - azilsartan medoxomil in the therapy of hypertension in patients with metabolic disorders